US 11,744,806 B2
Frigostable composition for iontophoretic transdermal delivery of a triptan compound
Michael Linn, Waldböckelheim (DE); Christoph Schmitz, Rheinbrohl (DE); and Hanshermann Franke, Hamburg (DE)
Assigned to LTS Lohmann Theraapie-Systeme AG, Andernach (DE)
Appl. No. 16/772,775
Filed by LTS Lohmann Therapie-Systeme AG, Andernach (DE)
PCT Filed Dec. 13, 2018, PCT No. PCT/EP2018/084699
§ 371(c)(1), (2) Date Jun. 13, 2020,
PCT Pub. No. WO2019/121293, PCT Pub. Date Jun. 27, 2019.
Claims priority of application No. 17208940 (EP), filed on Dec. 20, 2017.
Prior Publication US 2020/0323787 A1, Oct. 15, 2020
Int. Cl. A61K 9/70 (2006.01); A61K 9/00 (2006.01); A61K 31/4045 (2006.01); A61K 47/12 (2006.01); A61K 47/34 (2017.01)
CPC A61K 9/703 (2013.01) [A61K 9/0009 (2013.01); A61K 31/4045 (2013.01); A61K 47/12 (2013.01); A61K 47/34 (2013.01)] 22 Claims
 
1. A composition for iontophoretic transdermal delivery of a salt of a triptan compound, comprising:
a salt of a triptan compound,
a polyamine, in an amount ranging from 18 to 70%,
a dicarboxylic acid, and
water or an aqueous solvent mixture, and
wherein this composition is free of monocarboxylic acids and the water or aqueous solvent mixture is present in an amount ranging from 30 to 75 wt %.